Sponsor

Artiva Biotherapeutics, Inc.

Clinical research sponsor

Published trials3
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

3 shown
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114 · lead sponsor · 2025-07-09
RECRUITING
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsNCT05678205 · lead sponsor · 2023-08-01
WITHDRAWN
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.NCT06581562 · collaborator · 2024-05-15
RECRUITING

Sponsor roles

lead sponsor2
collaborator1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.